Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 8/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24654867 | 0.89 | KIF11 (0.42) | SCN10AKCNH2TRPV1PDE10AMETAP2 | |
| SCHEMBL19008535 | 0.86 | CYP1A2 (0.53) | SCN10AKCNH2TRPV1PDE10AMETAP2 | |
| SCHEMBL23479219 | 0.86 | ALDH1A1 (0.47) | TRPV1ALDH1A1MEN1KMT2ACYP1A2 | |
| SCHEMBL1695518 | 0.86 | TRPV1 (0.40) | SCN10AKCNH2TRPV1PDE10AMETAP2 | |
| SCHEMBL23479353 | 0.85 | TNKS (0.40) | KCNH2TRPV1ALDH1A1 | |
| SCHEMBL23478912 | 0.85 | HRH4 (0.38) | TRPV1ALDH1A1HPGDHSD17B10 | |
| SCHEMBL21863358 | 0.85 | SCN10A (0.38) | SCN10AKCNH2TRPV1PDE10AMETAP2 | |
| SCHEMBL7733556 | 0.85 | SCN10A (0.41) | SCN10AKCNH2TRPV1PDE10AMETAP2 | |
| SCHEMBL20515366 | 0.82 | EGFR (0.54) | TRPV1TDP1NPC1RAB9AMEN1 | |
| SCHEMBL16203494 | 0.82 | PDGFRB (0.55) | ALDH1A1HPGDNPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11446389-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | REGENERON PHARMACEUTICALS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20220259225-A1 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | REGENERON PHARMACEUTICALS, INC. | 2022-08-18 | — | — | US | disclosed |
| US-20170304272-A1 | ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2017-10-26 | — | — | US | disclosed |
| US-20170209591-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | REGENERON PHARMACEUTICALS, INC. | 2017-07-27 | — | — | US | disclosed |
| US-20160375147-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | REGENERON PHARMACEUTICALS, INC. | 2016-12-29 | — | — | US | disclosed |
| US-8178557-B2 | Compounds and methods of use | AMGEN INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20090176774-A1 | Compounds and methods of use | AMGEN INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160375147-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | SLC10A1, HNMT, OGFR | SCN10A 4001/4885KCNH2 4787/4885TRPV1 3943/4885 |
| US-20170209591-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | HNMT, SLC10A1, SLC10A2 | SCN10A 4104/4885KCNH2 4777/4885TRPV1 3758/4885 |
| US-20090176774-A1 | Compounds and methods of use | HGF, HGFAC, MET | SCN10A 4439/4885KCNH2 4774/4885TRPV1 3658/4885 |
| US-11446389-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | HNMT, SLC10A1, SLC10A2 | SCN10A 4104/4885KCNH2 4777/4885TRPV1 3758/4885 |
| US-20170304272-A1 | ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | FXR1, SLC10A1, NR1H4 | SCN10A 3114/4885KCNH2 4630/4885TRPV1 891/4885 |
| US-20220259225-A1 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | SLC10A1, HNMT, OGFR | SCN10A 4001/4885KCNH2 4787/4885TRPV1 3943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.